Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SWOG S1609
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
- NCT02834013 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Standard
We haven't built an HCP commentary report on SWOG S1609 (nivolumab plus ipilimumab; nivolumab in rare tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SWOG S1609 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 12 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Neuroendocrine Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Neoplasm of Unknown Primary; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Low Grade Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Penile Squamous Cell Carcinoma; Peritoneal Mesothelial Neoplasm; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
- Interventions
- Biospecimen Collection; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
- Arms
- Arm I (nivolumab, ipilimumab) · Experimental
- Arm II (nivolumab) · Experimental
- Enrollment
- 798
- Primary outcomes
- Overall response rate (ORR)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jan 30, 2017
- Primary completion
- May 1, 2026
- Results posted
- No
- Registry record
- NCT02834013 · updated Jun 17, 2026
Publications
linked from the registry- Chae YK, Sun R, Patel SP, Giles F, Ohr JP, Worden FP, Suga JM, Naing A, Cohen EE, Wallace J, Kang HS, Fenton S, Chung LI, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Othus M, Blanke CD, Kurzrock R. A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort. Ther Adv Med Oncol. 2026 Jul 23;18:17588359261451739. doi: 10.1177/17588359261451739. eCollection 2026. PubMed 42499790
- Chae YK, Czeskleba J, Patel SP, Mentor A, Robinson W, Jones NL, Rampurwala M, Naing A, Beck JM, Moloney-Lineen C, Chung LI, McLeod CM, Chen HX, Sharon E, Threlkel S, Othus M, Ryan CW, Blanke CD, Kurzrock R. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results. J Gynecol Oncol. 2026 Mar 25. doi: 10.3802/jgo.2026.37.e92. Online ahead of print. PubMed 41995270
- Swiecicki PL, Othus M, Patel SP, Kwang-Chae Y, Kurzrock R. Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609). Cancer. 2026 Apr 1;132(7):e70374. doi: 10.1002/cncr.70374. PubMed 41892875
- Chae YK, Othus M, Patel SP, Backes FJ, O'Malley DM, Cristea M, Naing A, Kurnit K, Eskander RN, T Goodrich S, Robinson WR, Scalici J, Chan J, Ali-Ahmad H, Hays J, McCormick C, Kim EJ, Sueblinvong T, Ahmed A, Siedel J, Thomes Pepin J, Bottsford-Miller JN, Fagbemi SO, Jaslowski AJ, Kim HS, Chung LI, Moloney-Lineen C, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. J Immunother Cancer. 2026 Feb 11;14(2):e012805. doi: 10.1136/jitc-2025-012805. PubMed 41672597
- Patel SP, Fisher J, Chae YK, Soto LS, Kasi A, Konda B, Walshauser M, Parra E, Zhang J, Duault C, Gonzalez-Kozlova E, Manyam G, Zhang J, Chen H, Duose DY, Laberiano Fernandez C, Luthra R, Al-Atrash G, Kim-Schulze S, Maecker HT, Wistuba II, Gnjatic S, Lee JJ, Zhang J, Magner CM, Chen HX, Sharon E, Othus M, Ryan CW, Blanke C, Haymaker CL, Kurzrock R. Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort. J Immunother Cancer. 2025 Jun 30;13(6):e011760. doi: 10.1136/jitc-2025-011760. PubMed 40588371
- Chae YK, Othus M, Patel SP, Aljumaily R, Win KZ, Pejovic T, Thomas SS, Robinson WR 3rd, Kim HS, Chung LI, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. Cancer Commun (Lond). 2025 Aug;45(8):976-986. doi: 10.1002/cac2.70020. Epub 2025 May 22. PubMed 40402690
- Patel SP, Cano-Linson E, Chae YK, Schokrpur S, Lao CD, Powers BC, Victor AI, Onitilo AA, Shin S, Takebe N, Threlkel S, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Blanke CD, Kurzrock R. Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma. NPJ Precis Oncol. 2025 Jan 24;9(1):24. doi: 10.1038/s41698-024-00798-1. PubMed 39856213
- Chae YK, Othus M, Patel SP, Gerber DE, Tanvetyanon T, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma). Ther Adv Med Oncol. 2024 Nov 22;16:17588359241293401. doi: 10.1177/17588359241293401. eCollection 2024. PubMed 39583952
- Chae YK, Othus M, Patel SP, Wilkinson KJ, Whitman-Purves EM, Lea J, Schallenkamp JM, Adra N, Appleman LJ, Alden M, Thomes Pepin J, Ellerton JA, Poklepovic A, Walter A, Rampurwala MM, Robinson WR, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer. Clin Cancer Res. 2024 Dec 16;30(24):5593-5600. doi: 10.1158/1078-0432.CCR-24-0606. PubMed 39417692
- Chae YK, Othus M, Patel S, Powers B, Hsueh CT, Govindarajan R, Bucur S, Kim HS, Chung LI, McLeod C, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke C, Kurzrock R. Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors. J Immunother Cancer. 2024 Sep 28;12(9):e009128. doi: 10.1136/jitc-2024-009128. PubMed 39343510
- Patel SP, Othus M, Chae YK, Huynh T, Tan B, Kuzel T, McLeod C, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke C, Kurzrock R. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort. J Immunother Cancer. 2024 Jul 27;12(7):e009074. doi: 10.1136/jitc-2024-009074. PubMed 39067873
- Patel SP, Guadarrama E, Chae YK, Dennis MJ, Powers BC, Liao CY, Ferri WA Jr, George TJ, Sharon E, Ryan CW, Othus M, Lopez G, Blanke CD, Kurzrock R. SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer. Cancer. 2024 Sep 1;130(17):2918-2927. doi: 10.1002/cncr.35243. Epub 2024 Feb 15. PubMed 38358334
- Othus M, Patel SP, Chae YK, Dietrich E, Streicher H, Sharon E, Kurzrock R. Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial. J Natl Cancer Inst. 2024 May 8;116(5):673-680. doi: 10.1093/jnci/djae009. PubMed 38243705
- Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy MP, Anderson SA, Zimmerman CT, O'Dea AP, Mirshahidi HR, Ahnert JR, Brescia FJ, Hahn O, Raymond JM, Biggs DD, Connolly RM, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res. 2022 Jan 15;28(2):271-278. doi: 10.1158/1078-0432.CCR-21-2182. Epub 2021 Oct 29. PubMed 34716198
- Wagner MJ, Othus M, Patel SP, Ryan C, Sangal A, Powers B, Budd GT, Victor AI, Hsueh CT, Chugh R, Nair S, Leu KM, Agulnik M, Sharon E, Mayerson E, Plets M, Blanke C, Streicher H, Chae YK, Kurzrock R. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021 Aug;9(8):e002990. doi: 10.1136/jitc-2021-002990. PubMed 34380663
- Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, Hayward J, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Plets M, Blanke CD, Kurzrock R. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer. 2021 Sep 1;127(17):3194-3201. doi: 10.1002/cncr.33591. Epub 2021 Apr 21. PubMed 33882143
- Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne). 2020 Dec 11;11:608422. doi: 10.3389/fendo.2020.608422. eCollection 2020. PubMed 33362722
- Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res. 2020 May 15;26(10):2290-2296. doi: 10.1158/1078-0432.CCR-19-3356. Epub 2020 Jan 22. PubMed 31969335